Evidence-based Clinical Guidelines for Eating Disorders: International Comparison by Hilbert, Anja et al.
1 
 
Evidence-based Clinical Guidelines for Eating Disorders: International Comparison  
 
Anja Hilbert,a* Hans Hoek,b, c, d Ricarda Schmidta 
 
a Department of Medical Psychology and Medical Sociology, Department of Psychosomatic 
Medicine and Psychotherapy, University of Leipzig Medical Center, Leipzig, Germany 
b Parnassia Psychiatric Institute, The Hague, The Netherlands  
c Department of Psychiatry, University Medical Center Groningen, University of Groningen, 
Groningen, The Netherlands  
d Department of Epidemiology, Columbia University, Mailman School of Public Health, New 
York (NY), USA 
 
 
* Corresponding author. Department of Medical Psychology and Medical Sociology, 
Department of Psychosomatic Medicine and Psychotherapy, University of Leipzig Medical 
Center, Philipp-Rosenthal-Strasse 27, 04103 Leipzig, Germany. Phone: +49 341 97-15361, 
Fax: +49 341 97-15359, Email: anja.hilbert@medizin.uni-leipzig.de. 
 
 




 Purpose of review – This systematic review sought to compare available evidence-
based clinical treatment guidelines for all specific eating disorders. 
 Recent findings – Nine evidence-based clinical treatment guidelines were located 
through a systematic search. The international comparison demonstrated notable 
commonalities and differences among current evidence-based clinical guidelines for eating 
disorders. Consistency across guidelines was greatest for treatments with a larger evidence 
base, while those with a lower evidence base had recommendations that varied considerably.  
 Summary – Evidence-based clinical guidelines represent an important step toward the 
dissemination and implementation of evidence-based treatments into clinical practice. Despite 
advances in clinical research on eating disorders, a growing body of literature demonstrates 
that individuals with eating disorders often do not receive an evidence-based treatment for 
their disorder. Regarding the dissemination and implementation of evidence-based treatments, 
current guidelines do endorse the main empirically validated treatment approaches with 
considerable agreement, but additional recommendations are largely inconsistent. An 
increased evidence base is critical in offering clinically reliable and consistent guidance for 
the treatment of eating disorders. Because developing and updating clinical guidelines is time-
consuming and complex, an international coordination of guideline development, for 
example, across the European Union, would be desirable.  





 Anorexia nervosa (AN), bulimia nervosa (BN), and binge-eating disorder (BED) 
represent the specific eating disorders defined in the Diagnostic and Statistical Manual of 
Mental Disorders, 5th Edition (DSM-5 [1]). They are characterized – at varying degrees – by 
persistent disturbances in eating or weight-control behavior and shape and weight 
overconcern. The central characteristic of AN is a significantly low body weight, induced by 
restriction of energy intake. The main features of BN and BED are recurrent binge-eating 
episodes. While individuals with BN usually attempt to prevent weight gain through 
inappropriate compensatory behaviors (e.g., self-induced vomiting), those with BED do not 
make recurrent use of them. All eating disorders result in significant impairments in health, 
psychosocial functioning, and quality of life [2,3]. Increased health care utilization and health 
care costs have been documented [4,5]. With a first onset that often occurs in adolescence or 
young adulthood [6], AN and BN show a long-term natural course with remission in more 
than 50% of cases, whereas evidence on the natural course of BED is scarce [7]. While AN 
occurs in up to 4% of young women [7,8], BN and BED have a lifetime prevalence of 1.0% 
and 1.9%, respectively [9].  
 Given the clinical significance of eating disorder symptomatology, over the past 
decades sustained effort has been placed on designing and evaluating psychological and 
medical treatments for eating disorders in rigorous, randomized-controlled efficacy studies 
[10–14]. Despite these advances, a growing body of literature demonstrates that individuals 
with eating disorders often do not receive an evidence-based treatment for their disorder 
[15,16]. For example, Kessler et al. [9] documented in 24,124 adults from 14 countries that 
only 47.4% of lifetime cases with BN and 38.3% of lifetime cases with BED ever received a 
specific treatment for their eating disorder. In a study among 5,658 women 40-50 years old 
from the United Kingdom (UK), only 27.4% of all women with a DSM-5 life-time diagnosis 
of an eating disorder had sought help or received treatment for an eating disorder at any point 
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in their life [17]. Multiple system factors (e.g., lack of screening for eating disorders) and 
personal patient factors (e.g., lack of information) may account for this “treatment gap” 
[15,18,19]. In addition, a “research-practice gap,” indicating a discrepancy between evidence-
based treatments and actual treatment delivery, was identified: As an example, the majority of 
eating disorder therapists do not adhere to evidence-based treatment protocols, but rather 
pursue eclectic combinations of interventions [20–22]; findings such as this highlight the 
significant challenge of disseminating and implementing of evidence-based eating disorder 
treatments into clinical practice [15,23,24]. 
 As a first step toward the dissemination and implementation of evidence-based 
treatments into clinical practice, evidence-based clinical guidelines for eating disorders were 
issued in several countries across the world. Their general aim is to inform clinical decision-
making of health care professionals and patients on efficacious interventions and treatment 
strategies. Based on a systematic search, selection, and evaluation of the treatment literature, 
evidence-based treatment guidelines offer specific recommendations in order to optimize 
patient care [25–27]. In one narrative review, Herpertz-Dahlmann et al. [28] compared several 
evidence-based clinical guidelines from four European countries (Germany, Spain, The 
Netherlands, and the UK) regarding the treatment of AN. They found correspondence in 
major recommendations, but no consensus on treatment intensity/setting, as well as no 
consensus and lack of evidence on nutritional rehabilitation and weight restoration. The 
authors identified a need for European research initiatives on AN in order to enhance the 
evidence base and clinical guidance. Since this report, several new guidelines were issued 
(e.g., The Netherlands, UK, Australia), however, current comparative information is lacking, 
especially for BN and BED. This systematic review sought to compare the available 
evidence-based clinical treatment guidelines for all specific eating disorders in order to 






 In May 2017, we systematically searched the electronic databases PubMed and 
Cochrane Database of Systematic Reviews (“guideline AND (eating disorder OR anorexia 
nervosa OR bulimia nervosa OR binge-eating disorder)”); the National Guideline 
Clearinghouse and the International Guideline Library (“eating disorder OR anorexia nervosa 
OR bulimia nervosa OR binge-eating disorder”); the website of the Academy of Eating 
Disorders through which partners and affiliate organizations were obtained and contacted; and 
contacted other experts in the field. Relevant clinical guidelines were required to be evidence-
based; the latest version; address the treatment of AN, BN, and/or BED; have a focus on 
adults; to be published in Dutch, German, or English; and have a national or international 
scope.  
 
Assessments and Analysis 
 In order to compare the content of the guidelines, key recommendations were 
summarized regarding pre-defined categories. For AN, BN, and BED, these categories 
included: first-line treatment setting, criteria for hospitalization, recommended treatment 
modalities including nutritional counseling, specific psychological interventions, and 
medications. For the treatment of AN, guidelines were additionally compared with respect to 
the following categories: compulsory treatment, criteria for partial hospitalization, criteria for 
discharge, recommended energy intake and weight gain, feeding supplements, and artificial 
feeding.  
 Included guidelines were independently examined by two authors. Relevant content 
was extracted into a pre-defined coding table using the guidelines’ original text by one author 
with corrections from the second author. For comparative purposes, it was noted whether a 
recommendation was given () or not reported (N.R.), and if possible, the guidelines’ 
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recommendations were recoded into three ratings: explicit recommendation in favor (+), 
recommendation requiring caution ((+)), and recommendation against (-). In addition, and if 
recoding was not possible, the guidelines’ recommendations were reported in text format.  
 
Results 
 A total of 33 guidelines were identified, as depicted in the PRISMA flow chart (Figure 
1). Most guidelines had to be excluded for not meeting the language criterion (n = 12). In 
addition, 5 guidelines were earlier versions of included guidelines, 4 guidelines were non-
evidence based, 2 guidelines solely focused on childhood eating disorders, and 1 guideline 
had a regional scope. Accordingly, 9 guidelines from 8 countries, published between 2009 
and 2017, were included in this report.  
 Most guidelines (n = 7) included treatment recommendations for AN, BN, and BED: 
these were the guidelines from Australia and New Zealand (AUS; [29]), Germany (GER; 
[30]), the Netherlands (NETH; [31]), Spain (SP; [32]), the United Kingdom (UK; [33]), the 
United States (US; [34,35]), and the World Federation of Societies of Biological Psychiatry 
(WFSBP; [36]). The guideline from Denmark (DEN; [37,38]) addressed the treatment of AN 
and BN, while the French guideline (FR; [39]) focused on AN only. All guidelines are 
described in Table 1. The guideline by the WFSBP provided recommendations for medical 
treatment of eating disorders only, whereas all other guidelines addressed several treatment 
approaches. The majority of guidelines were developed by multi-professional working groups 
(AUS, FR, GER, NETH, SP, UK), while both the US and WFSBP guidelines were developed 
by psychiatric groups. Regarding the modernity of the guidelines, 3 guidelines were published 
within the last 3 years (AUS, DEN, UK) or are currently being published (NETH), while the 





 The comparative results for AN, BN, and BED are summarized in Tables 2, 3, and 4.  
 Anorexia nervosa. All guidelines which provided information on the treatment setting 
(n = 7) consistently recommended outpatient treatment as a first-line therapy setting for 
patients with AN. For determining more intense levels of care, most guidelines provided 
criteria for partial (n = 5) and full-time hospitalization (n = 7). The degree of detail and range 
of hospitalization criteria varied between guidelines. However, the guidelines consistently 
emphasized the necessity to decide about hospitalization on an individual basis taking 
multiple factors into account. Overall, hospitalization should be considered for patients who 
have failed at outpatient care, or who are at high risk for medical complications as determined 
using patient’s weight status (e.g., extremely low body mass index), behavioral factors (e.g., 
decline in oral intake), vital signs (e.g., heart rate < 40 beats per minute), psychiatric 
comorbidity (e.g., suicide risk), or environmental aspects (e.g., family support). For very 
malnourished patients who do not consent to treatment, most guidelines provided some 
information on compulsory treatment (n = 7). Criteria for discharge from hospital were 
specified by the majority of guidelines (n = 7).  
The majority of guidelines (n = 6) emphasized the importance to treat patients with 
AN and eating disorders in general, respectively, by specialized professionals and/or by 
professionals with substantial experience in the treatment of eating disorders. Regarding 
specific treatment modalities, most guidelines included recommendations for nutritional 
management ranging from artificial feeding (n = 8) to general nutritional counseling (n = 6). 
Although the extent to which information on artificial feeding was given differed among 
guidelines (e.g., concerning refeeding practice, duration, or indication), guidelines 
consistently favored oral enteral nutrition over parenteral nutrition which should only be used 
as a last option. Regarding general nutritional counseling, 2 (GER, UK) of 6 guidelines 
explicitly stated that it should be part of a multidisciplinary therapy approach and not used as 
a stand-alone treatment. While there was substantial agreement across guidelines about the 
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amount of recommended weight gain per week in inpatient and outpatient settings, mostly 
ranging between 0.5-1.5 kg and 0.2-0.5 kg, respectively, variation in the amount of 
recommended energy intake per week was apparent. While some guidelines recommended 
daily energy intakes of 30-40 kcal/kg (GER, US) or higher (NETH), others recommended 
considerably lower intakes (SP, UK), particularly for severely malnourished patients at risk 
for refeeding syndrome. Among the 7 guidelines which specified the use of nutritional 
supplements, there was a large variation of recommendations regarding the type and 
indication for nutritional supplements. Some guidelines specifically recommended phosphate 
(n = 6), thiamine (n = 3), zinc (n = 2), or potassium (n = 2), if indicated, while others made a 
general recommendation for mineral or vitamin supplements (n = 3).  
Although psychotherapy was deemed a central part of treatment by all guidelines, only 
7 guidelines recommended specific psychological interventions. All 7 guidelines 
recommended family-based therapy (for greater detail, see Herpertz-Dahlmann in this issue; 
[40,41]), particularly for younger patients. For individual psychotherapy, most guidelines 
recommended cognitive-behavioral therapy (n = 6) which intervenes at the symptom level and 
centers on the modification of dysfunctional behaviors and cognitions that maintain the 
disorder [42]. It was recommended as a first-line psychotherapy for AN by 2 guidelines 
(NETH, UK). Lesser agreement was achieved for psychodynamic therapy and interpersonal 
psychotherapy, which were explicitly recommended as an alternative by 4 and 2 guidelines, 
respectively. While psychodynamic therapy includes treatments that operate on an 
interpretive-supportive continuum [43], interpersonal psychotherapy is a focused, goal-
oriented treatment which seeks to treat an eating disorder through resolving interpersonal 
problems in the context of what the disorder presents [44,45]. Further, the cognitive-
interpersonal approach Maudsley Anorexia Nervosa Treatment for Adults [46] and the 
Specialist Supportive Clinical Management [47,48] were recommended as first-line therapies 
by 2 guidelines (NETH, UK). While the German guideline only made a general 
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recommendation for psychological interventions, it recommended involving the patient’s 
family in the treatment of children and adolescents. Some guidelines noted that psychological 
interventions would be more effective in medically stabilized and cognitively improved 
patients (n = 3) or through combining psychological and nutritional interventions (n = 1). 
Regarding the pharmacological treatment of AN, 5 of 9 guidelines provided specific 
recommendations with some notable variations. Two guidelines made the general 
recommendation that medication should not be used as the sole or primary treatment for 
patients with AN (SP, UK) or that there is no specific medication to treat AN (FR). 
Antidepressants were generally recommended for those with depressive symptoms by 4 
guidelines. At the same time, the German guideline cautioned against the use of 
antidepressants for weight gain. For selective serotonin reuptake inhibitors (SSRIs), there was 
1 guideline which recommended its use for treating depressive symptoms in conjunction with 
psychotherapy or after weight restoration (US), while two other guidelines made general 
recommendations against their use, particularly in children and adolescents (AUS, NETH). 
The use of tricyclic antidepressants was not explicitly favored, given that there was 1 
recommendation against (US) and 1 cautious recommendation in favor (FR). The use of 
monoamine oxidase inhibitors (MAOIs) or bupropion, an atypical antidepressant, was not 
recommended by the US guideline, the only guideline reporting on these medications. Four 
guidelines consistently recommended the cautious use of antipsychotics for treating 
obsessional thinking in patients with AN, particularly olanzapine, because evidence from 
randomized-controlled trials and regarding long-term effects were lacking. Conflicting results 
were found for weight gain, given that 1 guideline recommended antipsychotics for weight 
gain (US) while another guideline stated that antipsychotics would not be appropriate for 
weight gain (GER). Pro-motility agents and anti-anxiety agents were only recommended by 
the US guideline for treating gastrointestinal problems and to reduce anticipatory anxiety 
concerning food intake, respectively. The use of appetizers and lithium was not recommended 
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by the German guideline. In addition, 4 guidelines consistently stated that estrogen should not 
be routinely offered to patients with AN, as this would depend on the patient’s menarche 
status or chronicity of AN, for example. 
Adjunctive treatment recommendations were rarely made and included meal support, 
eating training, and supervised physical activity, as described by the Danish guideline. 
Physical therapies (e.g., electroconvulsive therapy, transcranial magnetic stimulation) were 
not recommended by 2 guidelines. Of note, 4 guidelines included information on the medical 
management of AN and 3 guidelines additionally reported on pregnancy and pregnancy 
attempts. Two guidelines specifically provided information about the treatment of physical 
and mental comorbidities, as well as artificial feeding including refeeding syndrome.  
 Bulimia nervosa. Among the guidelines reporting on the prioritized treatment setting 
of BN, all recommended outpatient therapy as a first-line treatment (n = 5). Four and 5 
guidelines provided criteria for partial and full-time hospitalization, respectively. Regarding 
specific treatment modalities, nutritional counseling was generally recommended by the 
Danish guideline, in individualized or standardized format, while 2 other guidelines 
emphasized that nutritional interventions (e.g., to help develop a structured meal plan) should 
not be offered as stand-alone therapy (SP, US).   
Other than the WFSBP guideline, all available guidelines issued recommendations on 
specific psychological interventions. In agreement, 5 guidelines recommended cognitive-
behavioral therapy as a first-line psychotherapy for patients with BN, particularly in an 
individual format. The remaining 2 guidelines also made recommendations in favor of 
cognitive-behavioral interventions, but prioritized cognitive-behavioral, guided self-help 
treatment as a first-line treatment (UK), or did not provide an explicit treatment hierarchy 
(SP). Overall, among the 6 guidelines which recommended self-help approaches, 4 
highlighted the use of guided self-help based on cognitive-behavioral interventions (AUS, 
GER, NETH, UK), i.e., using structured self-help manuals supplemented with brief 
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supportive sessions [49]. Interpersonal psychotherapy was recommended as an alternative to 
cognitive-behavioral therapy by most guidelines (n = 4), while psychodynamic therapy (n = 2) 
was rarely recommended. Family-based therapy was in particular recommended for younger 
patients with BN (n = 4), and only explicitly recommended for adults by the US guideline. 
While the German guideline recommended cognitive-behavioral therapy for children and 
adolescents with BN, they emphasized the importance of including the patient’s family into 
treatment. Alternative psychological interventions were, for example, the combination of 
psychodynamic and cognitive-behavioral therapies (n = 1), couples therapy (n = 1), or support 
groups (n = 1).  
Among the recommendations for pharmacological treatment, 7 out of 8 guidelines 
consistently recommended antidepressants, specifically the SSRI fluoxetine, although with 
some restrictions (e.g., to use antidepressants in combination with psychotherapy). 
Conflicting recommendations were obtained for the use of tricyclic antidepressants such as 
imipramine and desipramine, which were recommended by the WFSBP, while the US 
guideline explicitly did not recommend tricyclic antidepressants for initial treatment in 
patients with BN. Consistently, 2 guidelines advised against the use of MAOIs (US, WFSBP). 
The use of anticonvulsants, specifically topiramate, was consistently recommended by 2 
guidelines, while the remaining guidelines did not report on anticonvulsants. The only 
guideline which made a recommendation about lithium cautioned against its use (US). For 
patients with comorbid obesity, 1 guideline recommended the anti-obesity medication orlistat 
(AUS).  
Of note, 4 guidelines included specific information about the treatment of 
comorbidities, and 3 guidelines made recommendations for the medical management of BN.  
 Binge-eating disorder. Only 3 out of 7 available guidelines explicitly included the 
recommendation that outpatient treatment is the first-line treatment setting for BED (GER, 
NETH, UK). Criteria for hospitalization were provided by 4 guidelines (AUS, GER, NETH, 
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UK). An explicit recommendation for nutritional counseling was made by the US guideline, 
specifically within the context of behavioral weight loss programs. The Spanish guideline 
generally recommended nutritional counseling for patients with eating disorders, with a 
psychiatrist’s approval.  
All guidelines provided recommendations for specific psychological interventions, 
except the WFSBP guideline. Cognitive-behavioral therapy was consistently recommended 
by all 6 guidelines, followed by guided (n = 6) or unguided (n = 2) cognitive-behavioral self-
help treatment and interpersonal psychotherapy (n = 4). An explicit recommendation for 
psychodynamic therapy was made by the German guideline only. With respect to first-line 
psychotherapy, 4 guidelines recommended cognitive-behavioral therapy, while 1 guideline 
favored guided cognitive-behavioral self-help treatment (UK). Regarding the treatment 
format, guidelines varied highly, with 1 guideline specifically recommending individual 
psychotherapy (AUS), 1 prioritizing group format (UK), and 2 guidelines not including any 
preference (NETH, US). Family-based treatment was recommended for children and 
adolescents with BED by the Dutch guideline only. 
The use of antidepressants was generally recommended by 3 guidelines (AUS, SP, 
US). These 3 guidelines and 3 other guidelines (GER, NETH, WFSBP) consistently made a 
specific recommendation in favor of SSRIs for reducing binge-eating episodes, at least in the 
short-term. For tricyclic antidepressants, only the WFSBP recommended their use, 
particularly imipramine. For anticonvulsants, 3 guidelines (AUS, US, WFSBP) consistently 
recommended the use of topiramate, while the remaining guidelines did not report on it. 
Consistently, 2 out of 2 guidelines reporting on anti-obesity medications explicitly 
recommended their use, specifically orlistat, for weight loss in patients with BED and 
comorbid obesity. In addition to weight loss, the anti-obesity medication sibutramine was 
recommended for reducing binge eating (US). Two guidelines explicitly made a 
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recommendation for pharmacological treatment in conjunction with psychological therapies 
(AUS, US). 
Of note, 3 guidelines reported on the treatment of comorbidities, and 2 guidelines 
made recommendations for the medical management of BED.   
 
Discussion 
 This systematic review of evidence-based clinical guidelines for eating disorders 
revealed many consistent recommendations, but also notable differences among the 
guidelines.  
 For the treatment of AN, the guidelines showed a substantial agreement on the amount 
of recommended weight gain, while recommended daily energy intakes varied considerably, 
which is consistent with Herpertz-Dahlmann et al. [28], who had narratively reviewed four 
European guidelines for the treatment of AN. Also in line with their findings, the 
recommendations for nutritional supplements varied widely, against a background of a lack of 
evidence. More consistently, most guidelines made recommendations for specific 
psychological interventions in the treatment of AN, especially for family-based therapy for 
younger patients, because of a large evidence base [40,50,51]. Most guidelines further 
supported cognitive-behavioral therapy [52]. Cognitive-behavioral therapy, the Maudsley 
Anorexia Nervosa Treatment for Adults, and the Specialist Supportive Clinical Management 
were even recommended as first-line therapies by the two current guidelines from the 
Netherlands and the UK, based on recently published results [53,54]. Little agreement was 
found for psychodynamic therapy and interpersonal psychotherapy as alternative treatments, 
because of scant evidence for their use [55–57]. A need for further research on the 
psychological treatment of AN was noted for all ages [28,58]. 
 Regarding pharmacotherapy of AN, recommendations varied widely – four guidelines, 
among them the medically-oriented WFSBP guideline, made no specific recommendation for 
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any medication, or advocated against their sole or primary use. The greatest level of 
consistency across four out of nine guidelines was found for the careful use of antipsychotics 
to reduce associated obsessional thinking in patients with AN, but it was inconsistent whether 
or not antipsychotics should be recommended for weight gain. In addition, three guidelines 
generally recommended antidepressants for the treatment of depressive symptoms, but a 
consistent recommendation for specific types of antidepressants (SSRIs, tricyclic 
antidepressants) could not be identified. Single guidelines’ recommendations emerged 
regarding other medications, for example, against the use of bupropion. Estrogen was with 
some consistency recommended to be offered only upon specific indication (see [59]). 
Overall, these inconsistent pharmacological recommendations for the treatment of AN may 
reflect the scarce evidence base for the pharmacological treatment of this disorder [13,28,60]. 
 For the treatment of BN, all guidelines but the medically-oriented WFSBP guideline 
issued recommendations on specific psychological interventions: The majority of them 
recommended cognitive-behavioral therapy as a first-line treatment for BN, reflecting the 
treatment literature [11,52]. In contrast, the UK guideline recommended offering cognitive-
behavioral self-help treatment first, presumably because of an emphasis on cost-effectiveness 
[27], for which initial data are available [61]. Interpersonal psychotherapy was recommended 
as an alternative to cognitive-behavioral therapy by the majority of guidelines, given its 
slower short-term efficacy, but equivalent long-term efficacy [52]. Psychodynamic therapy 
was recommended by the German and US guidelines only, despite its limited evidence base 
[62,63], possibly because of particularities in health care systems. Family-based therapy was 
recommended mostly for younger patients by half of the guidelines, which is supported by 
recent clinical research [64]. Most guidelines recommended self-help treatment, and the 
majority of these, especially the more recent guidelines, emphasized guided cognitive-
behavioral self-help treatment, documented to be efficacious in the treatment of BN [65]. A 
few recommendations with unclear rationale and/or sparse evidence base were issued for 
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alternative treatments (e.g., a combination of psychodynamic and cognitive-behavioral 
therapies) and nutritional counseling.  
 Regarding the pharmacological treatment of BN, most guidelines recommended 
antidepressants for the treatment of BN, specifically the SSRI fluoxetine, albeit with several 
restrictions (e.g., combined use with psychotherapy only). Fluoxetine has approval for the 
treatment of adults with BN in several countries (e.g., US, Germany). However, only a few 
and often inconsistent recommendations were made for the use of tricyclic antidepressants 
and anticonvulsants, specifically topiramate, and against the use of MAOIs and lithium. 
Again, these singular and contradictory recommendations may mirror the overall paucity of 
research on pharmacological treatments of BN [13].  
 For the treatment of BED, all guidelines provided recommendations for specific 
psychological interventions (except the medically-oriented WFSBP guideline). Cognitive-
behavioral therapy was consistently recommended by all respective guidelines and mostly as 
a first-line treatment, given its comprehensive evidence base [10, Hilbert A, Petroff D, 
Herpertz S, et al, unpublished data]. Cognitive-behavioral therapy was followed by cognitive-
behavioral self-help treatment, with the majority of guidelines recommending a guided 
format, a treatment with an increasing evidence base [65, Hilbert et al, unpublished data]. Of 
note, the guideline from the UK favored guided cognitive-behavioral self-help treatment as a 
first-line treatment, likely for economic reasons, as described for BN. Interpersonal 
psychotherapy was further recommended by the majority of the guidelines, based on a small 
number of studies [52, Hilbert et al, unpublished data]. An explicit non-evidence-based 
recommendation for psychodynamic therapy was made by the German guideline only [66] 
reflecting health care system specificities, while family-based treatment was recommended 
for children and adolescents with BED by the Dutch guideline only, based on emerging 
evidence for family-based treatment of adolescents with BN [64]. A recommendation for 
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nutritional counseling was made by two guidelines, which may reflect findings of lower 
efficacy of this treatment regarding binge-eating outcome [67, Hilbert et al, unpublished data].  
 Regarding the pharmacological treatment of BED, the majority of guidelines made a 
recommendation for SSRIs, which is in line with current literature [10], while only the 
WFSBP guideline recommended tricyclic antidepressants, based on studies published before 
1999. Three guidelines recommended the use of the anticonvulsant topiramate; however, the 
drug’s side-effects, especially cognitive impairment, have been noted [68]. Regarding anti-
obesity medications, two guidelines recommended orlistat for weight loss in BED and BN 
[69,70] and sibutramine for binge eating in BED, the latter being withdrawn from many 
markets because of adverse cardiovascular events. Combined psychological and 
pharmacological treatment was recommended by two guidelines; however, this is not 
supported by current evidence [71, Hilbert et al, unpublished data].  
 Overall, consistency across guidelines seemed to be the greatest for psychological 
treatments and for single medications with a larger evidence base, while for psychological and 
medical treatments with a smaller evidence base, recommendations varied considerably, and 
expert consensus played a greater role. Regarding the dissemination and implementation of 
evidence-based treatments into clinical practice, the guidelines thus do endorse main 
empirically validated treatment approaches with considerable agreement, but beyond this, the 
variability is greater in what recommendations evidence-based clinical guidelines subsume. A 
larger evidence base is critical in offering clinically reliable and consistent guidance in eating 
disorders, and many important areas of future clinical research have been identified for all 
eating disorders at different ages, given the treatment gap and the research-practice gap 
described at the outset of this article [15,22].  
 The available evidence is one reason for differences among guidelines. Among 
additional reasons, while several guidelines were issued within the past three years or are 
about to be published, the majority were five years and older. Especially for disorders such as 
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BED with a large recent increase in clinical research [Hilbert et al, unpublished data], changes 
in recommendations over time are to be expected. Several recommendations were non-
evidence-based and likely reflected particularities in health care systems, for example, the 
availability of outpatient, day patient, and inpatient settings or of therapists trained in a 
specific intervention. The guidelines differed as well in their scope, considering treatment in 
selected aspects (e.g., DEN, FR) or comprehensively (e.g., GER, US). Some guidelines were 
created by one health care profession or one specialized professional organization only (e.g., 
US, WFSBP), and may thus reflect the view of this profession only. Most guidelines, 
however, pursued a multi-professional approach in guideline development, and some of them 
noted the inclusion of other stakeholders as well. In fact, the current literature for guideline 
development advocates for broad stakeholder involvement of all relevant professions, health 
care providers, and patients [e.g., 25–27] for optimal acceptance and implementation.  
 Another additional source for differences among guidelines may be how the evidence 
was examined, with guidelines based on meta-analyses (e.g., GER, UK), systematic reviews 
(e.g., AUS, US), or unsystematic reviews of the evidence (e.g., FR). The transparency with 
which evidence was converted into specific recommendations further varied across 
guidelines; several guidelines explicitly evaluated the strength of evidence and provided clear 
rationale for a specific recommendation (e.g., GER, UK, WFSBP), while others did not (e.g., 
FR), leaving the empirical foundation of a recommendation unclear. To develop a guideline, it 
has been recommended to use a systematic approach to evaluate the strength of evidence, for 
example the Grading of Recommendations Assessment, Development, and Evaluation 
(GRADE; [72]), or the system of the Oxford Centre for Evidence-Based Medicine [73, see 
26]. For some guidelines, only summary statements without the systematic review component 
were available in the review languages, making the empirical background of a 
recommendation difficult to understand (e.g., DEN). Guidelines differed further in readability, 
with most guidelines providing clear or even standardized recommendations that were easily 
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located (e.g., GER, UK), while others provided them in a more complex text format (e.g., 
US). Although these aspects are central to the quality of a guideline, it is notable that a 
systematic quality evaluation [74] of clinical eating disorder guidelines is currently lacking; 
this was considered to be beyond the scope of this treatment-oriented review, but could help 
to systematically identify strengths and limitations of current eating disorder guidelines.  
 Strengths of this study were a systematic compilation of main treatment 
recommendations of current evidence-based eating disorders guidelines. Not within the scope 
of this review were: general setting-oriented recommendations (e.g., communication with the 
patient, therapeutic infrastructure, organization of transitions between different levels of care); 
methods for the identification, assessment, and diagnosis of eating disorders; and the practical 
applicability of the guidelines and their actual implementation in clinical settings. Several of 
these aspects warrant further investigation. One further limitation is that several guidelines 
had to be excluded from this review because of not meeting the language requirement. For 
further comparative research it would be desirable to have guidelines published not only in 
the national language, but also in other languages for international reception. 
 
Conclusion 
 This systematic, international comparison demonstrated notable commonalities and 
differences among current evidence-based clinical guidelines for eating disorders. Currently, 
several evidence-based clinical guidelines for eating disorders are in progress (e.g., GER, 
US). Because developing and updating clinical guidelines is time-consuming and complex, an 
international coordination of guideline development, for example, across the European Union, 
would be desirable. Collaborative efforts would need to carefully specify the goals and scope 
of a common “guideline trunc” which should be based on an elaborated, quality-assuring 
developmental process, while accounting for different cultures and national requirements. 
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European clinical studies on major research gaps could represent an important first step 
towards this end. 
 
Key points 
 The systematic review showed notable commonalities and differences among 
evidence-based clinical treatment guidelines for eating disorders.  
 Regarding the dissemination and implementation of evidence-based treatments, 
current guidelines endorse main empirically supported treatment approaches with 
considerable agreement, but additional recommendations are largely inconsistent.  
 An increased evidence base is critical in offering clinically reliable and consistent 
guidance for the treatment of eating disorders.  
 Because clinical guideline development is time-consuming and complex, an 




References and recommended reading 
Papers of particular interest, published within the annual period of review, have been 
highlighted as: * of special interest, ** of outstanding interest 
1. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5®). Washington, DC: American Psychiatric Association; 2013. 
2. Treasure J, Claudino AM, Zucker N. Eating disorders. Lancet 2010; 375:583–593. 
3. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to 
mental and substance use disorders: findings from the Global Burden of Disease Study 
2010. Lancet 2013; 382:1575–1586. 
20 
 
4. Agh T, Kovács G, Supina D, et al. A systematic review of the health-related quality of life 
and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. 
Eat Weight Disord 2016; 21:353–364.*A systematic summary of health-related quality of 
life and economic burden in the eating disorders 
5. Stuhldreher N, Konnopka A, Wild B, et al. Cost‐of‐illness studies and cost‐effectiveness 
analyses in eating disorders: a systematic review. Int J Eat Disord 2012; 45:476–491. 
6. Swanson SA, Crow SJ, Le Grange D, et al. Prevalence and correlates of eating disorders in 
adolescents: results from the national comorbidity survey replication adolescent 
supplement. Arch Gen Psychiatry 2011; 68:714–723. 
7. Smink FR, van Hoeken D, Hoek HW. Epidemiology, course, and outcome of eating 
disorders. Curr Opin Psychiat 2013; 26:543–548. 
8. Keski-Rahkonen A, Mustelin L. Epidemiology of eating disorders in Europe: prevalence, 
incidence, comorbidity, course, consequences, and risk factors. Curr Opin Psychiat 2016; 
29:340–345.*A narrative review of eating disorder prevalences from European countries 
9. Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating 
disorder in the World Health Organization World Mental Health Surveys. Biol Psychiat 
2013; 73:904–914. 
10. Brownley KA, Berkman ND, Peat CM, et al. Binge-eating disorder in adults: a systematic 
review and meta-analysis. Ann Intern Med 2016; 165:409–420.**A timely meta-analysis 
on the efficacy of psychological and medical approaches to the treatment of binge-eating 
disorder 
11. Hay P. A systematic review of evidence for psychological treatments in eating disorders: 
2005–2012. Int J Eat Disord 2013; 46:462–469. 
12. Kass AE, Kolko RP, Wilfley DE. Psychological treatments for eating disorders. Curr Opin 
Psychiat 2013; 26:549–555. 
21 
 
13. McElroy SL, Guerdjikova AI, Mori N, Keck PE Jr. Psychopharmacologic treatment of 
eating disorders: emerging findings. Curr Psychiatry Rep 2015; 17:35. 
14. Mitchell JE, Roerig J, Steffen K. Biological therapies for eating disorders. Int J Eat Disord 
2013; 46:470–477. 
15. Kazdin AE, Fitzsimmons‐Craft EE, Wilfley DE. Addressing critical gaps in the treatment 
of eating disorders. Int J Eat Disord 2017; 50:170–189.**A succinct overview of 
important gaps in the dissemination and implementation of evidence-based treatment into 
clinical practice 
16. Cooper M, Kelland H. Medication and psychotherapy in eating disorders: is there a gap 
between research and practice? J Eat Disord 2015; 3:45. 
17. Micali N, Martini MG, Thomas JJ, et al. Lifetime and 12-month prevalence of eating 
disorders amongst women in mid-life: a population-based study of diagnoses and risk 
factors. BMC Med 2017; 15:12.*A longitudinal study of mid-life prevalence rates of 
eating disorders in women in relation to psychosocial risk factors 
18. Peterson CB, Becker CB, Treasure J, et al. The three-legged stool of evidence-based 
practice in eating disorder treatment: research, clinical, and patient perspectives. BMC 
Med 2016; 14:69.*A narrative review of evidence-based practice in eating disorders 
19. Regan P, Cachelin FM, Minnick AM. Initial treatment seeking from professional health 
care providers for eating disorders: a review and synthesis of potential barriers to and 
facilitators of “first contact”. Int J Eat Disord 2017; 50:190–209.*A systematic review on 
treatment-seeking in the eating disorders 
20. Kosmerly S, Waller G, Robinson AL. Clinician adherence to guidelines in the delivery of 
family‐based therapy for eating disorders. Int J Eat Disord 2015; 48:223–229. 
21. Von Ranson KM, Wallace LM, Stevenson A. Psychotherapies provided for eating 
disorders by community clinicians: infrequent use of evidence-based treatment. 
Psychother Res 2013; 23:333–343. 
22 
 
22. Waller G. Treatment protocols for eating disorders: clinicians’ attitudes, concerns, 
adherence and difficulties delivering evidence-based psychological interventions. Curr 
Psychiat Rep 2016; 18:1–8.*A narrative review on the use of evidence-based treatment 
manuals in clinical practice 
23. Cooper Z, Bailey-Straebler S. Disseminating evidence-based psychological treatments for 
eating disorders. Curr Psychiat Rep 2015; 17:1–9. 
24. Fairburn CG, Wilson GT. The dissemination and implementation of psychological 
treatments: problems and solutions. Int J Eat Disord 2013; 46:516–521. 
25. Association of the Scientific Medical Societies in Germany – Standing Committee 
Guidelines [Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen 
Fachgesellschaften, AWMF – Ständige Kommission Leitlinien]. AWMF-Regulations 
Guidelines [AWMF-Regelwerk „Leitlinien“]. 2012. www.awmf.org/leitlinien/awmf-
regelwerk.html (accessed June 22, 2017). 
26. Institute of Medicine (IOM). Clinical Practice Guidelines We Can Trust. Washington, 
DC: The National Academies Press; 2011. doi.org/10.17226/13058 (accessed June 22, 
2017). 
27. National Institute for Health and Care Excellence (NICE). Developing NICE Guidelines: 
the Manual. 2014. nice.org.uk/process/pmg20 (accessed June 22, 2017). 
28. Herpertz-Dahlmann B, van Elburg A, Castro-Fornieles J, Schmidt U. ESCAP expert 
paper: new developments in the diagnosis and treatment of adolescent anorexia 
nervosa—a European perspective. Eur Child Adolesc Psychiatry 2015; 24:1153–1167. 
29. Hay P, Chinn D, Forbes D, et al. Royal Australian and New Zealand College of 
Psychiatrists clinical practice guidelines for the treatment of eating disorders. Aust N Z J 
Psychiatry 2014; 48:1–62. 
30. Association of the Scientific Medical Societies in Germany [Arbeitsgemeinschaft der 
Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF]. S3-Guideline for the 
23 
 
Assessment and Therapy of Eating Disorders [S3 Leitlinie Diagnostik und Therapie von 
Essstörungen]. 2010. www.awmf.org/leitlinien/detail/ll/051-026.html. (accessed June 22, 
2017). 
31. Dutch Foundation for Quality Development in Mental Healthcare. Practice guideline for 
the treatment of eating disorders [Zorgstandaard Eetstoornissen]. Utrecht: Netwerk 
Kwaliteitsontwikkeling GGz; 2017. 
32. Working Group of the Clinical Practice Guideline for Eating Disorders. Clinical Practice 
Guideline for Eating Disorders. Madrid: Quality Plan for the National Health System of 
the Ministry of Health and Consumer Affairs. Catalan Agency for Health Technology 
Assessment and Research; 2009. 
www.guiasalud.es/egpc/traduccion/ingles/conducta_alimentaria/completa/apartado00/pre
guntas.html (accessed June 22, 2017). 
33. National Institute for Health and Care Excellence (NICE). Eating Disorders: Recognition 
and Treatment, Full Guideline. 2017. www.nice.org.uk/guidance/ng69 (accessed June 22, 
2017). 
34. Yager J, Devlin MJ, Halmi KA, et al. Practice Guideline for the Treatment of Patients 
with Eating Disorders, 3rd Edition. APA; 2006. 
psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/eatingdisorder
s.pdf (accessed June 22, 2017). 
35. Yager J, Devlin MJ, Halmi KA, et al. Guideline Watch (August 2012): Practice Guideline 
for the Treatment of Patients with Eating Disorders, 3rd Edition. APA; 2012. 
psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/eatingdisorder
s-watch.pdf (accessed June 22, 2017).  
36. Aigner M, Treasure J, Kaye W, et al. World Federation of Societies of Biological 
Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. 
World J Biol Psychiatry 2011; 12:400–443.  
24 
 
37. Danish Health Authority. National Clinical Guideline for the Treatment of Anorexia 
Nervosa. Quick Guide. 2016. 
www.sst.dk/da/udgivelser/2016/~/media/36D31B378C164922BCD96573749AA206.ash
x (accessed June 22, 2017). 
38. Danish Health Authority. National Clinical Guideline for the Treatment of Moderate and 
Severe Bulimia. Quick Guide. 2016. www.sst.dk/en/publications/2015/national-clinical-
guideline-for-the-treatment-of-moderate-and-severe-bulimia (accessed June 22, 2017). 
39. Haute Autorité de Santé. Clinical Practice Guidelines: Anorexia Nervosa: management. 
2010. https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-
05/anorexia_nervosa_guidelines_2013-05-15_16-34-42_589.pdf (accessed June 22, 
2017). 
40. Blessitt E, Voulgari S, Eisler I. Family therapy for adolescent anorexia nervosa. Curr Opin 
Psychiatry 2015; 28:455–460. 
41. Lock J, Le Grange D, Agras WS, Dare C. Treatment Manual for Anorexia Nervosa. New 
York: Guilford Press; 2001. 
42. Fairburn CG. Cognitive Behavior Therapy and Eating Disorders. New York: Guilford 
Press; 2008. 
43. Leichsenring F, Luyten P, Hilsenroth MJ, et al. Psychodynamic therapy meets evidence-
based medicine: a systematic review using updated criteria. Lancet Psychiatry 2015; 
2:648–660.  
44. Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES. Interpersonal Psychotherapy 
of Depression. New York: Basic Books; 1984. 
45. McIntosh VV, Bulik CM, McKenzie JM, et al. Interpersonal psychotherapy for anorexia 
nervosa. Int J Eat Disord 2000; 27:125–139. 
25 
 
46. Schmidt U, Wade TD, Treasure J. The Maudsley Model of Anorexia Nervosa Treatment 
for Adults (MANTRA): development, key features, and preliminary evidence. J Cogn 
Psychother 2014; 28:48–71. 
47. McIntosh VV, Jordan J, Luty SE, et al. Specialist supportive clinical management for 
anorexia nervosa. Int J Eat Disord 2006; 39:625–632. 
48. McIntosh VV. Specialist supportive clinical management (SSCM) for anorexia nervosa: 
Content analysis, change over course of therapy, and relation to outcome. J Eat Disord 
2015; 3:O1. 
49. Wilson GT, Zandberg LJ. Cognitive-behavioral guided self-help for eating disorders: 
effectiveness and scalability. Clin Psychol Rev 2012; 32:343–357. 
50. Forsberg S, Lock J. Family-based treatment of child and adolescent eating disorders. 
Child Adolesc Psychiatr Clin N Am 2015; 24:617–629. 
51. Lock J. An update on evidence-based psychosocial treatments for eating disorders in 
children and adolescents. J Clin Child Adolesc Psychol 2015; 44:707–721. 
52. Kass AE, Kolko RP, Wilfley DE. Psychological treatments for eating disorders. Curr Opin 
Psychiatry 2013; 26:549–555. 
53. Byrne S, Wade T, Hay P, et al. A randomised controlled trial of three psychological 
treatments for anorexia nervosa. Psychol Med 2017; 1–11.**A current multicenter 
randomized-controlled trial on the efficacy of three psychological treatments for adults 
with anorexia nervosa 
54. Schmidt U, Ryan EG, Bartholdy S, et al. Two-year follow-up of the MOSAIC trial: a 
multicenter randomized controlled trial comparing two psychological treatments in adult 
outpatients with broadly defined anorexia nervosa. Int J Eat Disord 2016; 49:793–
800.**Two-year follow-up data on a multicenter randomized-controlled trial of two 
psychological treatments for adults with anorexia nervosa 
26 
 
55. Carter FA, Jordan J, McIntosh VV, et al. The long-term efficacy of three psychotherapies 
for anorexia nervosa: a randomized, controlled trial. Int J Eat Disord 2011; 44:647–654.  
56. McIntosh VV, Jordan J, Carter FA, et al. Three psychotherapies for anorexia nervosa: a 
randomized, controlled trial. Am J Psychiatry 2005; 162:741–747. 
57. Zipfel S, Wild B, Groß G, et al. Focal psychodynamic therapy, cognitive behaviour 
therapy, and optimised treatment as usual in outpatients with anorexia nervosa (ANTOP 
study): randomised controlled trial. Lancet 2014; 383:127–137.  
58. Hay PJ, Claudino AM, Touyz S, Abd Elbaky G. Individual psychological therapy in the 
outpatient treatment of adults with anorexia nervosa. Cochrane Database Syst Rev 2015; 
7:CD003909. 
59. Robinson L, Aldridge V, Clark EM, et al. Pharmacological treatment options for low bone 
mineral density and secondary osteoporosis in anorexia nervosa: a systematic review of 
the literature. J Psychosom Res 2017; 98:87–97.*A systematic review on bone mineral 
density in women with anorexia nervosa 
60. Miniati M, Mauri M, Ciberti A, et al. Psychopharmacological options for adult patients 
with anorexia nervosa. CNS Spectr 2016; 21:134–142.*A systematic review of 
pharmacological treatment of adult anorexia nervosa 
61. Lynch FL, Striegel-Moore RH, Dickerson JF, et al. Cost-effectiveness of guided self-help 
treatment for recurrent binge eating. J Consult Clin Psychol 2010; 78:322–333. 
62. Abbate-Daga G, Marzola E, Amianto F, Fassino S. A comprehensive review of 
psychodynamic treatments for eating disorders. Eat Weight Disord 2016; 21:553–580. 
63. Poulsen S, Lunn S, Daniel SI, et al. A randomized controlled trial of psychoanalytic 




64. Le Grange D, Lock J, Agras WS, et al. Randomized clinical trial of family-based 
treatment and cognitive-behavioral therapy for adolescent bulimia nervosa. J Am Acad 
Child Adolesc Psychiatry 2015; 54:886–894. 
65. Beintner I, Jacobi C, Schmidt UH. Participation and outcome in manualized self-help for 
bulimia nervosa and binge eating disorder – a systematic review and metaregression 
analysis. Clin Psychol Rev 2014; 34:158–176.  
66. Vocks S, Tuschen-Caffier B, Pietrowsky R, et al. Meta-analysis of the effectiveness of 
psychological and pharmacological treatments for binge eating disorder. Int J Eat Disord 
2010; 43:205–217. 
67. Grilo CM. Psychological and behavioral treatments for binge-eating disorder. J Clin 
Psychiatry 2017; 78 Suppl 1:20–24.**A succinct narrative review of psychological 
treatments for binge-eating disorder 
68. McElroy SL, Guerdjikova AI, Mori N, et al. Overview of the treatment of binge eating 
disorder. CNS Spectr 2015; 20:546–556. 
69. Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with 
binge eating disorder. Obes Res 2005; 13:1701–1708. 
70. Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and 
orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-
controlled trial. Biol Psychiatry 2005; 57:1193–1201. 
71. Grilo CM, Reas DL, Mitchell JE. Combining pharmacological and psychological 
treatments for binge eating disorder: current status, limitations, and future directions. 
Curr Psychiatry Rep 2016; 18:55.**A comprehensive review of randomized-controlled 
trials on combination treatments for binge-eating disorder 
72. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for Grading the Quality of 
Evidence and the Strength of Recommendations Using the GRADE Approach. Updated 
28 
 
October 2013. gdt.guidelinedevelopment.org/app/handbook/handbook.html (accessed 
June 22, 2017). 
73. Centre for Evidence-Based Medicine (CEBM). Oxford Centre for Evidence-based 
Medicine – Levels of Evidence (March 2009). 2009. www.cebm.net/oxford-centre-
evidence-based-medicine-levels-evidence-march-2009 (accessed June 22, 2017). 
74. Brouwers M, Kho ME, Browman GP, et al. AGREE II: Advancing guideline 




 The authors are grateful to Jamie L. Manwaring, Ph.D. and Lisa Opitz, B.Sc. for her 
help in editing this paper. 
 
Financial support and sponsorship 
 AH and RS are funded by the German Federal Ministry of Education and Research 
(grant 01EO1501).  
 
Conflicts of interest 
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professional 
Eating 
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AUS Royal Australian and New 
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Psychiatrists clinical 
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Active Royal Australian 















DEN National clinical guideline 
for the treatment of 
2016 Denmark Active Danish Health 
Authority 





Abbreviation Full guideline name 
 
Year Country Status Scientific society Target  Multi-
professional 
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anorexia nervosa – quick 
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clinical guideline for the 
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quick guide [38] 
FR Clinical practice guidelines 
anorexia nervosa: 
management [39] 
2010 France Active Association 

















Abbreviation Full guideline name 
 
Year Country Status Scientific society Target  Multi-
professional 
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Haute Autorité de 
Santé 
GER S3-guideline for the 
assessment and therapy of 
eating disorders [30] 
2010 Germany In revision Association of 
the Scientific 
Medical Societies 
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Year Country Status Scientific society Target  Multi-
professional 
Eating 
disorders   
 specialists Carers and 
patients  
SP Clinical practice guideline 
for Eating Disorders [32] 















involved in the 












Abbreviation Full guideline name 
 
Year Country Status Scientific society Target  Multi-
professional 
Eating 
disorders   
UK Eating disorders: 
recognition and treatment, 
full guideline [33] 
2017 United 
Kingdom 
Active National Institute 












US Practice guideline for the 
treatment of patients with 
eating disorders, third 
edition, Guideline watch 













who are in active 
clinical practice 








Abbreviation Full guideline name 
 
Year Country Status Scientific society Target  Multi-
professional 
Eating 
disorders   
involved in 
research or other 
academic 
endeavors 
WFSBP World Federation of 
Societies of Biological 
Psychiatry (WFSBP) 
guidelines for the 
pharmacological treatment 
of eating disorders [36] 
2011 - Active World Federation 









Note. N.R. not reported; AN anorexia nervosa; BN bulimia nervosa; BED binge-eating disorder; italicized words indicate that the information was 





Table 2  
Comparison of evidence-based clinical guidelines for anorexia nervosa regarding key recommendations  
 Clinical guideline 
Recommendation AUS DEN FR GER NETH SP UK US WFSBP 
Treatment setting          
First-line treatment: 
outpatient 
+ N.R. + +  + +  + +  N.R. 
Criteria for day 
hospital treatment 
N.R. N.R.   N.R.    N.R. 
Criteria for 
hospitalization 
 N.R.       N.R. 




N.R. N.R.       N.R. 
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weight gain per 
week, inpatient 
settings 




0.5-1.5 kg  0.5-1 kg N.R.  0.9-1.4 kg N.R. 
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Nutritional 
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 Clinical guideline 
Recommendation AUS DEN FR GER NETH SP UK US WFSBP 
FBT +* +* +* N.R. +*  +* +* +* N.R. 
Psychodynamic 
therapy 
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Medication N.R. N.R. (No 
specific 
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N.R. N.R. (+)  N.R. N.R. N.R. N.R. - N.R. 
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Appetizers N.R. N.R. N.R. - N.R. N.R. N.R. N.R. N.R. 
Lithium N.R. N.R. N.R. - N.R. N.R. N.R. N.R. N.R. 
Estrogen N.R. N.R. (+) N.R. N.R. (+)  (+)  (+)  N.R. 
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Recommendation AUS DEN FR GER NETH SP UK US WFSBP 
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Note.  recommendation given; + explicit recommendation in favor; (+) cautious recommendation in favor; - recommendation against; N.R. no 
recommendation reported; AUS Australia and New Zealand; CBT cognitive-behavioral therapy; Den Denmark; FBT family-based therapy; FR 





Anorexia Nervosa Treatment for Adults; NETH The Netherlands; SSCM Specialist Supportive Clinical Management; SSRI selective serotonin 
reuptake inhibitor; SP Spain; UK United Kingdom; US United States; WFSBP World Federation of Societies of Biological Psychiatry;  
a recommendations for weight gain and energy intake were derived from both the guideline’s text and recommendations; binformation on energy 
intake for the UK guideline was obtained from the Management of Really Sick Patients with Anorexia Nervosa (MARSIPAN) guideline, because 








Comparison of evidence-based clinical guidelines for bulimia nervosa regarding key recommendations 
 Clinical guideline 
 AUS DEN GER NETH SP UK US WFSBP 
Treatment setting         
First-line treatment: 
outpatient 
+ N.R. + N.R. + + +  N.R. 
Criteria for day hospital 
treatment 
 N.R.  N.R. N.R.   N.R. 
Criteria for inpatient 
treatment 
 N.R.  N.R.    N.R.  
Treatment modalities         
















 Clinical guideline 






N.R. + N.R. N.R. N.R. N.R. N.R. 
CBT + (1st) + (1st, 
individual or 
group) 
+ (1st) + (1st, 
individual 
or group)  
+ + 
(Individual) 
+ (1st) N.R. 
FBT N.R. +* N.R. +* N.R. +* + N.R. 
Self-help + (Guided, 
CBT) 










N.R. N.R. + N.R. N.R. N.R. +  N.R. 
IPT N.R. N.R. + + + N.R. + N.R. 





 Clinical guideline 



















 Clinical guideline 
 AUS DEN GER NETH SP UK US WFSBP 
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Medications + (If 
psychothera










nts are not 
recommend
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(Not as sole 
treatment) 
N.R. N.R. 
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 AUS DEN GER NETH SP UK US WFSBP 
Other + Weight 
loss 
(orlistat) 
N.R. N.R. N.R. N.R. N.R. N.R. N.R. 
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 AUS DEN GER NETH SP UK US WFSBP 
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Note.  recommendation given; + explicit recommendation in favor; (+) cautious recommendation in favor; - recommendation against; N.R. no 
recommendation reported; AUS Australia and New Zealand; CBT cognitive-behavioral therapy; Den Denmark; FBT family-based therapy; GER 
Germany; IPT interpersonal therapy; MAOI monoamine oxidase inhibitor; NETH The Netherlands; SSRI selective serotonin reuptake inhibitor; SP 
Spain; UK United Kingdom; US United States; WFSBP World Federation of Societies of Biological Psychiatry; *indicates that the recommended 







Comparison of evidence-based clinical guidelines for binge-eating disorder regarding key recommendations 
 Clinical guideline 
 AUS GER NETH SP UK US WFSBP 
Treatment setting        
First-line treatment: outpatient N.R. + + N.R. + N.R. N.R. 
Criteria for inpatient treatment    N.R.  N.R. N.R. 
Treatment modalities        
Nutritional counseling N.R. N.R. N.R. (+) (With 
approval of 
psychiatrist) 







Psychological interventions + 
(Individual) 





 Clinical guideline 
 AUS GER NETH SP UK US WFSBP 
CBT + (1st) + (1st) + (1st, 
individual or 
group) 






FBT N.R. N.R. +* N.R. N.R. N.R. N.R. 















Psychodynamic therapies N.R. + N.R. N.R. N.R. N.R. N.R. 
IPT N.R. + + +  N.R. + N.R. 
Medications + (If 
psychotherap
y is not 
available or 
as adjunctive 







 Clinical guideline 
 AUS GER NETH SP UK US WFSBP 
therapy) 
Antidepressants + N.R. N.R. +  N.R. + N.R. 


























Antiobesity medications + Weight 
loss (orlistat) 









 Clinical guideline 
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 No long-term 
evidence 
Note.  recommendation given; + explicit recommendation in favor; (+) cautious recommendation in favor; - recommendation against; N.R. no 





interpersonal therapy; MAOI monoamine oxidase inhibitor; NETH The Netherlands; SSRI selective serotonin reuptake inhibitor; SP Spain; UK 
United Kingdom; US United States; WFSBP World Federation of Societies of Biological Psychiatry; *indicates that the recommended intervention 







Figure 1. PRISMA Flow Diagram: International comparison of evidence-based clinical 
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